

Alessandro Cataliotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/227925/publications.pdf>

Version: 2024-02-01

153
papers

7,329
citations

53794

45
h-index

54911

84
g-index

170
all docs

170
docs citations

170
times ranked

6577
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. <i>Lancet, The</i> , 2001, 358, 2113-2117.	13.7	993
2	Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. <i>Circulation</i> , 2002, 105, 1354-1359.	1.6	485
3	Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. <i>Kidney International</i> , 2004, 65, 1492-1498.	5.2	299
4	Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases. <i>Circulation Research</i> , 2002, 91, 1127-1134.	4.5	271
5	Cardiac Natriuretic Peptides Are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1508-1515.	6.1	270
6	Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 17442-17447.	7.1	256
7	Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. <i>Kidney International</i> , 2002, 61, 609-614.	5.2	247
8	Prognostic Impact of the Indexation of Left Ventricular Mass in Patients Undergoing Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2768-2774.	6.1	246
9	Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. <i>European Heart Journal</i> , 2013, 34, 886-893.	2.2	222
10	Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. <i>Kidney International</i> , 2002, 62, 339-345.	5.2	194
11	Prognostic Value of Echocardiographic Indicators of Left Ventricular Systolic Function in Asymptomatic Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1029-1037.	6.1	180
12	Circulating Natriuretic Peptide Concentrations in Patients With End-Stage Renal Disease: Role of Brain Natriuretic Peptide as a Biomarker for Ventricular Remodeling. <i>Mayo Clinic Proceedings</i> , 2001, 76, 1111-1119.	3.0	179
13	Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide. <i>Hypertension</i> , 2006, 47, 874-880.	2.7	150
14	Diagnostic potential of cardiac natriuretic peptides in dialysis patients. <i>Kidney International</i> , 2001, 59, 1559-1566.	5.2	145
15	Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease. <i>Hypertension</i> , 2002, 40, 41-46.	2.7	123
16	The Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide for Death and Cardiovascular Events in Healthy Normal and Stage A/B Heart Failure Subjects. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2140-2147.	2.8	114
17	Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure. <i>Circulation</i> , 2004, 109, 1680-1685.	1.6	104
18	Immunoreactivity and Guanosine 3',5'-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide. <i>Hypertension</i> , 2007, 49, 1114-1119.	2.7	104

#	ARTICLE	IF	CITATIONS
19	Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure. <i>Circulation</i> , 2003, 107, 686-689.	1.6	98
20	Conflicting vascular and metabolic impact of the IL-33/sST2 axis. <i>Cardiovascular Research</i> , 2018, 114, 1578-1594.	3.8	96
21	Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure. <i>Hypertension</i> , 2007, 49, 1128-1133.	2.7	91
22	A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community. <i>Journal of the American College of Cardiology</i> , 2011, 58, 629-636.	2.8	91
23	Novel Protein Therapeutics for Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2305-2312.	2.8	89
24	Ryanodine receptor dispersion disrupts Ca ²⁺ release in failing cardiac myocytes. <i>ELife</i> , 2018, 7, .	6.0	84
25	Human Hypertension Is Characterized by a Lack of Activation of the Antihypertensive Cardiac Hormones ANP and BNP. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1558-1565.	2.8	82
26	Cardiotrophin-1 Stimulation of Cardiac Fibroblast Growth. <i>Circulation Research</i> , 2002, 90, 128-134.	4.5	81
27	Long-Term Cardiac pro-B-Type Natriuretic Peptide Gene Delivery Prevents the Development of Hypertensive Heart Disease in Spontaneously Hypertensive Rats. <i>Circulation</i> , 2011, 123, 1297-1305.	1.6	76
28	Circulating Aldosterone and Natriuretic Peptides in the General Community. <i>Hypertension</i> , 2015, 65, 45-53.	2.7	74
29	Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012, 302, R292-R299.	1.8	67
30	Pro-B-Type Natriuretic Peptide ¹⁻¹⁰⁸ Circulates in the General Community. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1386-1395.	2.8	65
31	Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3',5'-Monophosphate and Decreases Mean Arterial Pressure. <i>Circulation</i> , 2005, 112, 836-840.	1.6	63
32	Maximizing the Renal Cyclic 3',5'-Guanosine Monophosphate System with Type V Phosphodiesterase Inhibition and Exogenous Natriuretic Peptide: A Novel Strategy to Improve Renal Function in Experimental Overt Heart Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2742-2747.	6.1	59
33	A Human Atrial Natriuretic Peptide Gene Mutation Reveals a Novel Peptide With Enhanced Blood Pressure-Lowering, Renal-Enhancing, and Aldosterone-Suppressing Actions. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1024-1032.	2.8	58
34	Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 2000, 36, 945-952.	1.9	56
35	BNP-induced activation of cGMP in human cardiac fibroblasts: Interactions with fibronectin and natriuretic peptide receptors. <i>Journal of Cellular Physiology</i> , 2006, 209, 943-949.	4.1	55
36	Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H1529-H1535.	3.2	54

#	ARTICLE	IF	CITATIONS
37	Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up Study. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1154-1160.	3.0	54
38	Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 405-419.	2.8	54
39	B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival. <i>Hypertension</i> , 2015, 66, 199-210.	2.7	52
40	Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. <i>Kidney International</i> , 2005, 67, 1723-1730.	5.2	50
41	Secretion of Glycosylated Pro-B-Type Natriuretic Peptide from Normal Cardiomyocytes. <i>Clinical Chemistry</i> , 2011, 57, 864-873.	3.2	50
42	Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. <i>Frontiers in Endocrinology</i> , 2017, 8, 160.	3.5	50
43	Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2611-2617.	6.1	48
44	Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2004, 43, 479-484.	1.9	47
45	Influence of Glycosylation on Diagnostic and Prognostic Accuracy of N-Terminal Pro-B-Type Natriuretic Peptide in Acute Dyspnea: Data from the Akershus Cardiac Examination 2 Study. <i>Clinical Chemistry</i> , 2015, 61, 1087-1097.	3.2	47
46	IL-33 (Interleukin 33)/sST2 Axis in Hypertension and Heart Failure. <i>Hypertension</i> , 2018, 72, 818-828.	2.7	44
47	Angiotensin II AT ₁ receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 284, F1115-F1119.	2.7	40
48	A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension. <i>Hypertension</i> , 2010, 56, 1152-1159.	2.7	40
49	Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure. <i>Circulation</i> , 2002, 105, 639-644.	1.6	38
50	Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2005, 288, R1093-R1097.	1.8	34
51	Seasonal variations of hyponatremia in the emergency department: Age-related changes. <i>American Journal of Emergency Medicine</i> , 2017, 35, 749-752.	1.6	33
52	Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F943-F952.	2.7	32
53	Long-term effects of moderate protein diet on renal function and low-grade inflammation in older adults with type 2 diabetes and chronic kidney disease. <i>Nutrition</i> , 2014, 30, 1045-1049.	2.4	32
54	Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II-Mediated Hypertension. <i>Circulation</i> , 2008, 118, 1729-1736.	1.6	30

#	ARTICLE	IF	CITATIONS
55	Mâ€Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics. <i>Journal of the American Heart Association</i> , 2014, 3, e000206.	3.7	30
56	Diagnosis of Renovascular Disease by Extra- and Intrarenal Doppler Parameters. <i>Angiology</i> , 1998, 49, 707-721.	1.8	29
57	CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 283, F464-F472.	2.7	28
58	Endothelin A Receptor Antagonism in Experimental Congestive Heart Failure Results in Augmentation of the Renin-Angiotensin System and Sustained Sodium Retention. <i>Circulation</i> , 2004, 109, 249-254.	1.6	28
59	Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease. <i>Hypertension</i> , 2003, 41, 88-92.	2.7	27
60	Sustained Blood Pressureâ€“Lowering Actions of Subcutaneous B-Type Natriuretic Peptide (Nesiritide) in a Patient With Uncontrolled Hypertension. <i>Mayo Clinic Proceedings</i> , 2012, 87, 413-415.	3.0	27
61	Renal and Anti-Aldosterone Actions of Vasopressin-2 Receptor Antagonism and B-Type Natriuretic Peptide in Experimental Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 412-419.	3.9	24
62	Endothelial permeability in vitro and in vivo: Protective actions of ANP and omapatrilat in experimental atherosclerosis. <i>Peptides</i> , 2013, 48, 21-26.	2.4	24
63	Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. <i>Journal of Hypertension</i> , 2003, 21, 1355-1362.	0.5	23
64	Local Renal Delivery of a Natriuretic Peptide. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1302-1308.	2.8	22
65	Regional diastolic dysfunction in post-infarction heart failure: role of local mechanical load and SERCA expression. <i>Cardiovascular Research</i> , 2019, 115, 752-764.	3.8	22
66	Ventricular cardiostrophin-1 activation precedes BNP in experimental heart failure. <i>Peptides</i> , 2003, 24, 889-892.	2.4	18
67	Cardiostrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells. <i>Peptides</i> , 2002, 23, 1441-1447.	2.4	17
68	Leukemia inhibitory factor is augmented in the heart in experimental heart failure. <i>European Journal of Heart Failure</i> , 2003, 5, 137-145.	7.1	17
69	B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 296, R1744-R1750.	1.8	17
70	Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload. <i>ESC Heart Failure</i> , 2021, 8, 918-927.	3.1	17
71	Changes of protein kinetics in nephrotic patients. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2002, 5, 51-54.	2.5	15
72	Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure. <i>European Journal of Heart Failure</i> , 2006, 8, 681-686.	7.1	14

#	ARTICLE	IF	CITATIONS
73	Cardiac BNP gene delivery prolongs survival in aged spontaneously hypertensive rats with overt hypertensive heart disease. <i>Aging</i> , 2014, 6, 311-319.	3.1	14
74	Natriuretic Peptides: Novel Therapeutic Targets in Heart Failure. <i>Journal of Investigative Medicine</i> , 2005, 53, 378-384.	1.6	13
75	Natriuretic Peptides as Regulators of Myocardial Structure and Function: Pathophysiologic and Therapeutic Implications. <i>Heart Failure Clinics</i> , 2006, 2, 269-276.	2.1	13
76	Oral Brain Natriuretic Peptide: A Novel Strategy for Chronic Protein Therapy for Cardiovascular Disease. <i>Trends in Cardiovascular Medicine</i> , 2007, 17, 10-14.	4.9	13
77	Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart. <i>Regulatory Peptides</i> , 2003, 112, 161-166.	1.9	11
78	Effect of Plasma Protein Depletion on BNP-32 Recovery. <i>Clinical Chemistry</i> , 2008, 54, 933-934.	3.2	11
79	Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage. <i>Hypertension</i> , 2020, 75, 1195-1204.	2.7	11
80	Early cardiac-chamber-specific fingerprints in heart failure with preserved ejection fraction detected by FTIR and Raman spectroscopic techniques. <i>Scientific Reports</i> , 2022, 12, 3440.	3.3	11
81	Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction. <i>Hypertension</i> , 2007, 50, 481-488.	2.7	7
82	Impact of left ventricular remodeling and renal function on 24h-ECG recordings and cardiovascular outcome in elderly hypertensive patients. <i>European Journal of Internal Medicine</i> , 2016, 29, 71-77.	2.2	7
83	B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease. <i>Kidney International</i> , 2017, 92, 657-668.	5.2	7
84	B-Type Natriuretic Peptide: Beyond a Diagnostic. <i>Heart Failure Clinics</i> , 2008, 4, 449-454.	2.1	6
85	Serum sodium correction rate and the outcome in severe hyponatremia. <i>American Journal of Emergency Medicine</i> , 2017, 35, 1691-1694.	1.6	6
86	In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 11.	2.4	6
87	Atrial Natriuretic Peptide ³¹⁻⁶⁷ : A Novel Therapeutic Factor for Cardiovascular Diseases. <i>Frontiers in Physiology</i> , 2021, 12, 691407.	2.8	6
88	Congestive Heart Failure: Pharmacological Agents and the Potential of B-Type Natriuretic Peptide. <i>Current Medicinal Chemistry</i> , 2005, 12, 1439-1447.	2.4	5
89	Soluble E-Selectin Is an Inverse and Independent Predictor of Left Ventricular Wall Thickness in End-Stage Renal Disease Patients. <i>Nephron Clinical Practice</i> , 2010, 114, c74-c80.	2.3	5
90	Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0142103.	2.5	4

#	ARTICLE	IF	CITATIONS
91	Sildenafil, a phosphodiesterase V inhibitor potentiates the renal actions of subcutaneously administered BNP without adverse hemodynamic effects in experimental overt heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, S19.	1.7	3
92	Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension. <i>Blood Pressure</i> , 2021, 30, 31-40.	1.5	3
93	Biological Actions of a Novel Oral Human BNP in an Experimental Model of Acute Hypertension. <i>Journal of Cardiac Failure</i> , 2006, 12, S30.	1.7	2
94	Chronic subcutaneous administration of BNP in human heart failure for eight weeks: a pilot study to establish safety and lack of tolerance. <i>Journal of Cardiac Failure</i> , 2003, 9, S59.	1.7	1
95	Renal resistance to BNP in severe experimental heart failure is overcome with high dose Nesiritide. <i>Journal of Cardiac Failure</i> , 2004, 10, S45.	1.7	1
96	Specific roles for the natriuretic peptides as biomarkers in coronary artery disease and left ventricular dysfunction. <i>Journal of Cardiac Failure</i> , 2004, 10, S47.	1.7	1
97	Renal actions of the cancionÂ® Cardiac Recovery System in severe experimental heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, S66.	1.7	1
98	Pilot study assessing dose and tolerability of BNP (nesiritide) infusion post anterior myocardial infarction to prevent adverse left ventricular remodeling and heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, S82.	1.7	1
99	Potent cardiorenal actions in experimental heart failure with dual activation of soluble and particulate guanylate cyclases by bay 58-2667 and B-type natriuretic peptide: a novel therapeutic strategy. <i>Journal of Cardiac Failure</i> , 2004, 10, S90.	1.7	1
100	Differential Biological Actions and Assay Detection of Altered Forms of BNP In Vitro. <i>Journal of Cardiac Failure</i> , 2006, 12, S29.	1.7	1
101	AlbuBNP, a Recombinant Human B-Type Natriuretic Peptide and Serum Albumin Fusion Hormone Has Prolonged Natriuretic, Glomerular Filtration Rate Enhancing and Aldosterone Inhibiting Properties. <i>Journal of Cardiac Failure</i> , 2006, 12, S84.	1.7	1
102	AlbuBNP (Cardeva), a Novel Recombinant Human B-Type Natriuretic Peptide Serum Albumin Fusion Protein Has Prolonged Renal Enhancing Properties When Compared to Human BNP. <i>Journal of Cardiac Failure</i> , 2007, 13, S145.	1.7	1
103	Association of NPPA rs5065 Genetic Variant With Increased Cardiovascular Risk in the General USA Population. <i>Journal of Cardiac Failure</i> , 2010, 16, S76.	1.7	1
104	Novel Protein Therapeutics for Chronic Systolic Heart Failure: Chronic Subcutaneous BNP Administration (NICE BNP). <i>Journal of Cardiac Failure</i> , 2010, 16, 912-913.	1.7	1
105	Hepatocyte Growth Factor and Cardiomyopathy in Dialysis Patients. <i>Hypertension</i> , 2012, 60, e24; author reply e25-6.	2.7	1
106	M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, .	2.4	1
107	BNP enhances renal actions of lasix and suppresses lasix-induced aldosterone activation in experimental heart failure. <i>American Journal of Hypertension</i> , 2003, 16, A22.	2.0	0
108	Natriuretic and anti-aldosterone actions of chronic oral neutral endopeptidase inhibition during the progression of experimental congestive heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, S17.	1.7	0

#	ARTICLE	IF	CITATIONS
109	Oral administration of newly developed conjugated form of human brain natriuretic peptide reduced blood pressure and enhances CGMP production in normal conscious dogs. <i>Journal of Cardiac Failure</i> , 2004, 10, S43.	1.7	0
110	Subcutaneous administration of biologically active novel conjugates of human BNP in normal conscious dogs. <i>Journal of Cardiac Failure</i> , 2004, 10, S47.	1.7	0
111	Differential actions of cardiac resynchronization therapy upon ANP and BNP in patients with non-ischemic and ischemic cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2004, 10, S49.	1.7	0
112	Effect of cardiac resynchronization therapy on plasma catecholamines in patients with and without beta-blocker therapy. <i>Journal of Cardiac Failure</i> , 2004, 10, S62.	1.7	0
113	Effect of cardiac resynchronization therapy on serum creatinine levels in patients with congestive heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, S63.	1.7	0
114	Response to Do Commercially Available Assay Kits for B-Type Natriuretic Peptide Measure Pro-BNP1-108, as Well as BNP1-32?. <i>Hypertension</i> , 2007, 50, .	2.7	0
115	Transition from Asymptomatic to Overt Systolic Heart Failure – Renal, Hemodynamic and Neurohumoral Adaptations. <i>Journal of Cardiac Failure</i> , 2008, 14, S16.	1.7	0
116	Kidney-Heart Connection: Experimental Mild Renal Insufficiency Induces Early Cardiac Fibrosis and Myocardial Diastolic Dysfunction Followed by Late Systolic Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, S17.	1.7	0
117	Heart-Kidney Connection: Myocardial Infarction Induces Renal Cortical and Medullary Fibrosis and Activation of Renal Molecular Remodeling in the Absence of Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, S24.	1.7	0
118	Furin and Corin Process Human ProBNP to Unique BNP Forms In Vitro with Differential Regulation of Furin and Corin in Models of Experimental Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, S33.	1.7	0
119	Is Cystatin C a Biomarker for Proatherogenic Factors and Early Renal Insufficiency in Human Coronary Artery Disease without Systolic Dysfunction?. <i>Journal of Cardiac Failure</i> , 2008, 14, S38.	1.7	0
120	Incremental Burden of CRI in the General Population and Added Predictive Power of GFR Together with BNP and NT-proBNP in Detection of Altered Ventricular Structure and Function. <i>Journal of Cardiac Failure</i> , 2008, 14, S84.	1.7	0
121	Novel Renal Targeted Protein Therapeutics in Experimental Overt Heart Failure and Renal Dysfunction with an Innovative Chimeric Natriuretic Peptide: ABC-NP. <i>Journal of Cardiac Failure</i> , 2008, 14, S76.	1.7	0
122	Mutation of three amino acids in the disulfide-ring of a CNP based chimeric natriuretic peptide alters its vascular properties. <i>BMC Pharmacology</i> , 2009, 9, .	0.4	0
123	Pro-B-Type Natriuretic Peptide: A Novel, Specific Biomarker for Detection of Left Ventricular Dysfunction in the General Community. <i>Journal of Cardiac Failure</i> , 2009, 15, S82-S83.	1.7	0
124	Amino Terminal Pro-B-Type Natriuretic Peptide Predicts Mortality, Congestive Heart Failure, Stroke and Myocardial Infarction in the General Population but Not in the Absence of Traditional Cardiovascular Risk Factors or Structural Changes of the Heart. <i>Journal of Cardiac Failure</i> , 2009, 15, S85.	1.7	0
125	Chronic Renal Insufficiency: Prevalence in the General Population and Improved Detection of Cardiac Disease in Combination with BNP Assays. <i>Journal of Cardiac Failure</i> , 2009, 15, S85.	1.7	0
126	The Degree of Natriuretic Peptide System Activation in Stable and High Risk Chf Characterized by Increased Cystatin C Is Not Reflected in cGMP Activation. <i>Journal of Cardiac Failure</i> , 2009, 15, S36.	1.7	0

#	ARTICLE	IF	CITATIONS
127	Cardio-Humoral Actions of the Phosphodiesterase-V Inhibitor Vardenafil in Experimental Diabetic Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2009, 15, S7.	1.7	0
128	A Genetic Variant of the ANP Gene Is Associated With a Lower Cardiometabolic Risk Profile in the General USA Population. <i>Journal of Cardiac Failure</i> , 2010, 16, S4.	1.7	0
129	Novel Large Animal Model of Acute Experimental Hypertensive Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, S14-S15.	1.7	0
130	Myocardial Specific BNP Gene-Delivery Improves Diastolic Function and Ventricular Structure in Spontaneous Hypertensive Rodents. <i>Journal of Cardiac Failure</i> , 2010, 16, S72.	1.7	0
131	Pro-B-Type Natriuretic Peptide Predicts Mortality and Cardiovascular Events in the General Community: Comparison to Other BNP Biomarkers. <i>Journal of Cardiac Failure</i> , 2010, 16, S76.	1.7	0
132	In Vitro and In Vivo Actions of a Novel ANP Genetic Variant: Unique Actions on Human Endothelial Cells. <i>Journal of Cardiac Failure</i> , 2011, 17, S10.	1.7	0
133	M-Atrial Natriuretic Peptide and Nitroglycerin in a Model of Acute Hypertensive Heart Failure: A Comparison of Two cGMP Therapeutics. <i>Journal of Cardiac Failure</i> , 2011, 17, S12.	1.7	0
134	Early Experimental Chronic Kidney Disease Activates Myocardial Apoptotic Genes and Leads to Early Myocardial Fibrosis. <i>Journal of Cardiac Failure</i> , 2011, 17, S13.	1.7	0
135	Chronic Cardiac Gene Delivery of proBNP in Experimental Progressive Hypertensive Heart Disease Improves Survival. <i>Journal of Cardiac Failure</i> , 2011, 17, S22.	1.7	0
136	Cardiorenal Actions of the Designer Natriuretic Peptide, CD-NP, in a Severe Heart Failure Model Treated with Furosemide. <i>Journal of Cardiac Failure</i> , 2011, 17, S62.	1.7	0
137	Effects of long-term proBNP cardiac gene delivery in experimental hypertensive heart disease. <i>BMC Pharmacology</i> , 2011, 11, .	0.4	0
138	Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure. <i>BMC Pharmacology</i> , 2011, 11, .	0.4	0
139	The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure. <i>BMC Pharmacology</i> , 2011, 11, .	0.4	0
140	C-Type natriuretic peptide: a potential urinary biomarker for renal remodeling and fibrosis during aging. <i>BMC Pharmacology</i> , 2011, 11, .	0.4	0
141	Impaired Cardiorenal Adaptation to Acute Heart Failure and Volume Expansion in a Large Animal Model of Mild Renal Insufficiency: New Insights Into the Kidney-Heart Connection. <i>Journal of Cardiac Failure</i> , 2012, 18, S11.	1.7	0
142	Progressive Bi-Ventricular Dysfunction in a Large Animal Model of Heart Failure With Rapid Ventricular Pacing: Echocardiographic Parameters and Invasive Characterization. <i>Journal of Cardiac Failure</i> , 2012, 18, S16.	1.7	0
143	Cardiac Specific Gene Delivery of a Dual GC-A and GC-B Agonist, CD-NP, Mediates Anti-Hypertrophic Actions in a Model of Hypertensive Heart Disease beyond GC-A Activation Alone Via BNP. <i>Journal of Cardiac Failure</i> , 2012, 18, S25.	1.7	0
144	The Newly Designed Dual Guanylyl Cyclase A and B Activator, CU-NP, Elicits Fibro-Suppressing and Favorable Cardiorenal Hemodynamic Actions. <i>Journal of Cardiac Failure</i> , 2012, 18, S27.	1.7	0

#	ARTICLE	IF	CITATIONS
145	Activation of Heme-Free Soluble Guanylate Cyclase With Cinaciguat Has Beneficial Cardiorenal Actions When Added to Furosemide in Experimental Heart Failure. <i>Journal of Cardiac Failure</i> , 2012, 18, S63.	1.7	0
146	Subcutaneous Deliver of M-ANP in Conscious Canines: An Innovative Designer Guanylyl Cyclase A Receptor Activator for Cardiovascular Disease. <i>Journal of Cardiac Failure</i> , 2012, 18, S63-S64.	1.7	0
147	Chronic Subcutaneous BNP Administration in Human Preclinical Systolic Dysfunction (Stage B Heart) Tj ETQq1 1 0.784314 rgBT /Ove Failure, 2013, 19, S3.	1.7	0
148	Furosemide Dose Reduction in Patients with Stable Systolic Heart Failure and Renal Insufficiency Improves Renal Function without Compromising Clinical Status. <i>Journal of Cardiac Failure</i> , 2013, 19, S68.	1.7	0
149	Novel Protein Therapeutics for Human Preclinical Diastolic Dysfunction (Stage B Heart Failure): Chronic SQ BNP Administration. <i>Journal of Cardiac Failure</i> , 2013, 19, S65.	1.7	0
150	Aldosterone in the General Community: Biomarker or Mediator of Cardiorenal and Metabolic Disease. <i>Journal of Cardiac Failure</i> , 2013, 19, S4.	1.7	0
151	M-Atrial Natriuretic Peptide: A Novel Designer Natriuretic Peptide with Sustained Blood Pressure Lowering and Cyclic GMP Activating Actions in a Chronic Canine Model of Angiotensin II-Induced Hypertension. <i>Journal of Cardiac Failure</i> , 2014, 20, S2.	1.7	0
152	8. Guanylyl Cyclase A-Targeted Gene Therapy Ameliorates Disease Progression in Autosomal Recessive Polycystic Kidney Disease. <i>Molecular Therapy</i> , 2015, 23, S4.	8.2	0
153	Distorted assessment of left atrial size by echocardiography in patients with increased aortic root diameter. <i>Egyptian Heart Journal</i> , 2021, 73, 55.	1.2	0